العربية
العملة SYP
Benign Prostatic Hypertrophy شراء في حلب
شراء Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy

Benign Prostatic Hypertrophy

من السلع المنتجة
توافر
تحديد السعر من البائع
Shipping:
البائع
  سوريا, حلب
(المكان على الخريطة)
+963 
عرض الهواتف
وصف
Alfuzosine is a quinazoline derivative, efficient when administered in oral form. It is a selective-antagonist of alpha - 1 post-synaptic adrenergic receptors. In Vitro studies confirmed the specificity of Alfuzosine toward receptors situated at the level of vesical trigone, ureter and prostata. In Vivo studies indicated that Alfuzosine decreases the uretral pressures and then the resistance to the miction's flow. On the Cardiovascular level, Alfuzosine has an antihypertensive effect. PHARMACOKINETICS : - Alfuzosine is readily absorbed after oral administration. - Peak plasma concentrations generally occur 3 hours after an oral dose. - Bioavailability is about 64 % . - It is metabolised in the liver and excreted primarily in faeces via the bile. - About 11 % of a dose is excreted unchanged in the urine. - Plasma elimination half-life is of 3 to 5 hours. - It is 90 % bound to plasma proteins. - The metabolites have no pharmacodynamic action. - In older patients, the absorption of Alfuzosine is faster and bioavailability values are increased, however the elimination rate is not affected. - In renal failure the Alfuzosine clearance increases due to an increase in the free portion. - Chronic severe renal failure (creatinine clearance between 15 - 40 ml /min) is not worsened by the use of Alfuzosine. - The pharmacokinetic profile of Alfuzosine is not modified in case of chronic cardiac failure.
الاتصال بالبائع
Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
طريقة التوصيل
قارن0
مسحالعناصر المحددة: 0
    Placing, selling, advertising and/or realization of this service/product is prohibited by operating legislation. Go to main page